Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: A case report

American Journal of Hematology

Volumn 81, Issue 2, 2006, Pages 121-123

  Hayashi, Tomoe ^a   Morishita, Eriko ^a   Ontachi, Yasuo ^a   Yamazaki, Masahide ^a   Asakura, Hidesaku ^a   Yoshida, Takashi ^b   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Chronic graft versus host disease; PDGF; Sarpogrelate hydrochloride; TGF

Indexed keywords

CYCLOSPORIN A; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; SARPOGRELATE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

ABSENCE OF SIDE EFFECTS; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CONTRACTURE; HUMAN; MALE; MORBIDITY; MORTALITY; PIGMENT DISORDER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RAYNAUD PHENOMENON; SKIN ATROPHY; SKIN DEFECT; SKIN PIGMENTATION; SYSTEMIC SCLEROSIS; THERMOGRAPHY;

ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; MALE; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SEROTONIN ANTAGONISTS; SUCCINATES; TRANSFORMING GROWTH FACTOR BETA;

EID: 32144447796     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20511     Document Type: Article

References (11)

1. Ratanatharathorn V, Ayash L, Lazarus HM, et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121-129.
2. Michallet M, Perrin MC, Belhabri A, et al. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23: 145-150.
3. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001;97:1196-1201.
4. Nishioka K, Katayama I, Kondo H, et al. Evaluation of drug therapy for Raynoud phenomenon in progressive systemic sclerosis. Study Report 1995; Scleroderma Research Group meeting held in Japan, 1996:248-257 (in Japanese).
5. 2 receptor antagonist. J Dermatol 2000;27:643-650.
6. Varga J, Jimenez SA. Modulation of collagen gene expression: its relation to fibrosis in systemic sclerosis and other disorders. Ann Intern Med 1995;122:60-62.
7. Mauch C, Eckes B, Krieg T, et al. Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993;100:92S-96S.
8. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-511.
9. Kawaguchi Y. IL-1 alpha gene expression and protein production by fibroblasts from patients from patients with systemic sclerosis. Clin Exp Immunol 1994;97:445-450.
10. Zhang Y, McCormick LL, Gilliam AC, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168:3088-3098.
11. McCormick LL, Zhang Y, Gilliam AC, et al. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999;163:5693-5699.